Opens in a new tab or window The FDA approved tenecteplase (TNKase) for adult stroke patients, Genentech announced on Monday. A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is ...

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several ... on the modified Rankin scale (mRS). Tenecteplase is a genetically ...

The US Food and Drug Administration has approved the thrombolytic tenecteplase for the treatment of patients with acute ischemic stroke, manufacturer Genentech ... of patients with a modified Rankin ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...

The usage of tenecteplase in patients with acute ischemic stroke was associated with similar effectiveness and safety ...

The researchers found that the percentage of patients with a modified Rankin scale score of 0 or 1 at 90 days was higher with intra-arterial tenecteplase versus standard medical treatment after ...

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...